Seasonally calm start to the year
Nexstim published its Q1 business update on Friday. The company reported that it delivered two NBS systems during the period. Deliveries were slightly below our expectations in a seasonally slow start to the year. Based on the new data, we are modestly lowering our forecasts for the coming years. There have been no material changes in the valuation picture of the share. The stock is cheaply priced, but the risks are also elevated due to low visibility and a tight financial situation.
Nexstim
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read more on company pageKey Estimate Figures28.04
2023 | 24e | 25e | |
---|---|---|---|
Revenue | 7.2 | 8.3 | 10.8 |
growth-% | -23.93 % | 14.85 % | 30.31 % |
EBIT (adj.) | -1.2 | -0.7 | 0.6 |
EBIT-% (adj.) | -16.94 % | -8.53 % | 5.43 % |
EPS (adj.) | -0.18 | -0.11 | 0.07 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | 122.07 |
EV/EBITDA | - | 604.16 | 49.42 |